Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma

scholarly article

Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma is …
instance of (P31):
scholarly articleQ13442814

External links are
P819ADS bibcode2006PNAS..103.2352G
P356DOI10.1073/PNAS.0510441103
P932PMC publication ID1413716
P698PubMed publication ID16461462
P5875ResearchGate publication ID7313727

P50authorElías CampoQ5830202
Hans Konrad Müller-HermelinkQ19284834
Elaine JaffeQ19647268
Andreas RosenwaldQ28379725
Jan DelabieQ28379730
Randy D GascoyneQ87831803
Dennis D WeisenburgerQ87934333
Julie M VoseQ87934467
James O ArmitageQ87934469
Wing C ChanQ87934470
Brian E PikeQ91982950
Timothy GreinerQ92884271
Rita M. BrazielQ114521837
Joseph G HaciaQ117253672
P2093author name stringLouis M Staudt
Mazen W Karaman
German Ott
Kai Fu
Vincent V Ho
Chiranjib Dasgupta
Lynette M Smith
James C Lynch
Michael Y Im
P2860cites workDesign and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examplesQ24569561
Comparisons of substitution, insertion and deletion probes for resequencing and mutational analysis using oligonucleotide microarraysQ24792059
Nonparametric Estimation from Incomplete ObservationsQ25938997
PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencingQ29618564
Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study GroupQ33947282
11q deletions in hematological malignanciesQ34293480
Ataxia telangiectasia gene mutations in leukaemia and lymphomaQ34295109
From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decadesQ34514539
ATM mutations in sporadic lymphoid tumours.Q34980360
Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphomaQ34983013
ATM deficiency and oxidative stress: a new dimension of defective response to DNA damageQ35037470
Mantle cell lymphoma is characterized by inactivation of the ATM geneQ35081325
Mantle cell lymphoma: established therapeutic options and future directionsQ35605571
Strategies for mutational analysis of the large multiexon ATM gene using high-density oligonucleotide arraysQ38330003
Analysis of ataxia-telangiectasia mutated (ATM)- and Nijmegen breakage syndrome (NBS)-regulated gene expression patternsQ38345473
Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.Q38350727
Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survivalQ38584605
Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.Q40479135
Contribution of the Atm protein to maintaining cellular homeostasis evidenced by continuous activation of the AP-1 pathway in Atm-deficient brainsQ42434974
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalancesQ43833429
Familial lymphoid neoplasms in patients with mantle cell lymphoma.Q47952452
Oligonucleotide microarray based detection of repetitive sequence changesQ52073326
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphomaQ57279573
p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomasQ58110137
p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosisQ71099778
Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphomaQ73168699
Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification ProjectQ77306442
Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation statusQ80809839
Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridizationQ80894677
Absence of ATM hypermethylation in mantle cell and follicular lymphomaQ81471268
P433issue7
P407language of work or nameEnglishQ1860
P921main subjectataxia telangiectasiaQ387082
P304page(s)2352-2357
P577publication date2006-02-03
P1433published inProceedings of the National Academy of Sciences of the United States of AmericaQ1146531
P1476titleMutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma
P478volume103

Reverse relations

cites work (P2860)
Q41362934A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Q41893268ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis
Q90399238ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Q37633188ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
Q89996308Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma
Q91819920Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study
Q30498194Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
Q51511748Apoptosis and Expression of the Bcl-2 Family of Proteins and P53 in Human Pancreatic Ductal Adenocarcinoma
Q41689585Ataxia-Telangiectasia Mutated (ATM) Protein Signaling Participates in Development of Pulmonary Arterial Hypertension in Rats.
Q42553373CCMCL1: a new model of aggressive mantle cell lymphoma
Q34135450Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma
Q53542728Characterization of genetic changes in MCL by interphase FISH on tissue sections
Q39406673Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms
Q37447203Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome
Q93087086Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
Q39218048DNA damage response and hematological malignancy
Q35828767Development of a murine model for blastoid variant mantle-cell lymphoma
Q93223071Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Q36238650Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
Q39819083Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.
Q37629080Gene mutations and actionable genetic lesions in mantle cell lymphoma.
Q38819164Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets
Q98281008Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study
Q37269010Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma
Q35483623HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
Q42106883Histone deacetylase inhibitors as cancer therapeutics
Q28304924Identification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disorders
Q57415016Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
Q33934010Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma
Q89974125Inflammatory Infiltrate and Angiogenesis in Mantle Cell Lymphoma
Q54543199Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Q51529244Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.
Q39888339MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
Q36290246Molecular pathogenesis of mantle cell lymphoma
Q36447932Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma
Q42011578Novel therapies for aggressive B-cell lymphoma
Q31164228Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice
Q34074921Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling
Q83921246Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma
Q41044103Proteomics analyses of human optic nerve head astrocytes following biomechanical strain.
Q38763829Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop
Q38840443Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation
Q26858960Risk factors for etiology and prognosis of mantle cell lymphoma
Q39695835Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair
Q36629194Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature
Q44418379TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage
Q36889248Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles.
Q37705182Telomeres and telomerase in normal and malignant B-cells.
Q59808738The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies
Q41472998The awakening of the CDK10/Cyclin M protein kinase
Q33585273The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells
Q36216258The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index
Q55007581The molecular pathogenesis of mantle cell lymphoma.
Q42040698The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis
Q36267279The spectrum of ATM missense variants and their contribution to contralateral breast cancer
Q38658549Will new drugs change the standard of care for patients with mantle cell lymphoma?

Search more.